ABT-263 (Navitoclax; CAS 923564-51-6) is an orally bioavailable small molecule inhibitor targeting anti-apoptotic proteins of the Bcl-2 family, including Bcl-2, Bcl-xl, and Bcl-w. By disrupting interactions between these anti-apoptotic factors and pro-apoptotic proteins (Bim, Bad, Bak), ABT-263 promotes activation of caspase-dependent apoptotic pathways, resulting in programmed cell death. This compound is utilized extensively in oncology research to explore apoptotic mechanisms and evaluate antitumor efficacy in various cancer models.
References:
1. Tse et al., ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor. Cancer Res. 2008, 68, 3421-3428.
2. Shoemaker et al., Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models. Clin. Cancer Res. 2008, 14, 3268-3277
- 1. Kevin Berthenet, Serena Diazzi, et al. "Atypical contribution of caspase-3 to melanoma cancer cell motility by regulation of coronin 1B activity." Cell Death Dis. 2025 Oct 6;16(1):690. PMID: 41053010
- 2. Nicholas W Harper, Gavin A Birdsall, et al. "RNA Pol II inhibition activates cell death independently from the loss of transcription." Cell. 2025 Aug 14:S0092-8674(25)00856-6. PMID: 40818455
- 3. Rebecca A. DeStefanis, Alexa E. Schmitz, et al. "BCL-2 Family Inhibition Enhances mTORC1/2 Inhibition in PIK3CA-Mutant Colorectal Cancer." Mol Cancer Ther. 2025 Jul 10. PMID: 40635161
- 4. Nadezhda Alexandrovna Orlova, Maria Valerievna Sinegubova, et al. "Genomic and Phenotypic Characterization of CHO 4BGD Cells with Quad Knockout and Overexpression of Two Housekeeping Genes That Allow for Metabolic Selection and Extended Fed-Batch Culturing." Cells. 2025 May 11;14(10):692. PMID: 40422195
- 5. Zhengyu Wang, Bo-Syong Pan, et al. "CD36-mediated endocytosis of proteolysis-targeting chimeras." Cell. 2025 Jun 12;188(12):3219-3237.e18. PMID: 40250420
- 6. Renya Zeng, Xingcheng Chen, et al. "FGFR4 inhibition augments paclitaxel-induced cell death in ovarian cancer." Int Immunopharmacol. 2025 May 16:155:114626. PMID: 40245772
| Storage | Desiccate at -20°C |
| M.Wt | 974.61 |
| Cas No. | 923564-51-6 |
| Formula | C47H55ClF3N5O6S3 |
| Synonyms | Navitoclax,ABT-263,ABT263,ABT 263 |
| Solubility | ≥48.73 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O |
| Chemical Name | (R)-4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((4-morpholino-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide |
| Canonical SMILES | O=S(C1=CC(S(NC(C2=CC=C(N3CCN(CC4=C(CCC(C)(C4)C)C5=CC=C(Cl)C=C5)CC3)C=C2)=O)(=O)=O)=CC=C1N[C@H](CCN6CCOCC6)CSC7=CC=CC=C7)(C(F)(F)F)=O |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment:[1] | |
| Cell lines | Murine DO11.10 T-hybridoma cells expressing murine Bcl-2, Bcl-xL and Bcl-w proteins |
| Preparation method | The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months. |
| Reaction Conditions | None specifc suggestion |
| Applications | ABT-263 is an antitumor effector in preclinical and early clinical studies. It binds to Bcl-2, Bcl-xL, and Bcl-w in vitro, but only targets Bcl-2 in vivo. In human non-Hodgkin lymphomas, high expression of Bcl-2 sensitized to ABT-263 elevated proapoptotic Bim. |
| Animal experiment:[2] | |
| Animal models | Immune-deficient NOD/SCID or NOD/SCID, ILγ receptor negative mice |
| Dosage form | Orally taken at 100 mg/kg/day for 21 days |
| Applications | ABT-263 can largely inhibited the activity of patient-derived pediatric acute lymphoblastic leukemia xenograft. ABT-263 sensitivity was correlated with low MCL1 mRNA expression levels. BH3 profiling revealed that resistance to ABT-263 correlated with mitochondrial priming by NOXA peptide. |
| Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
| References: 1. Mérino D1, Khaw SL, Glaser SP et al. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.Blood. 2012 Jun 14;119(24):5807-16. 2. Suryani S, Carol H, Chonghaile TN et al. Cell and Molecular Determinants of In Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts. Clin Cancer Res. 2014 Jul 10. | |
| ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM. | ||||||
| Targets | Bcl-xL | Bcl-2 | Bcl-w | |||
| IC50 | ≤ 0.5 nM (Ki) | ≤1 nM (Ki) | ≤ 1 nM (Ki) | |||
Quality Control & MSDS
- View current batch:
